Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia

被引:10
作者
Franchini, M
Gandini, G
Veneri, D
de Matteis, G
Federici, F
Solero, P
Aprili, G
机构
[1] Univ Verona, Dept Clin & Expt Med, Hematol Sect, I-37100 Verona, Italy
[2] Hosp Verona, Immunhematol & Transfus Serv, Verona, Italy
[3] Hosp Verona, Inst Chem Clin Anal, Verona, Italy
关键词
D O I
10.1111/j.1537-2995.2004.03264.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Transfusional iron overload is a frequent finding in long-term survivors of acute leukemia (AL). Only a few studies have reported the results of iron depletion therapy in this category of patients. STUDY DESIGN AND METHODS: Between January 1996 and July 2003, 26 consecutive adult patients who achieved complete remission of AL and developed transfusional iron overload underwent a weekly phlebotomy program at our transfusion center. Serum ferritin levels and transferrin saturation were monitored during the iron depletion therapy and the follow-up period. These AL patients were also checked for the presence of 12 hereditary hemochromatosis (HH) gene mutations. RESULTS: After a mean follow-up of 57.8 months, therapeutic phlebotomy (mean number of units collected, 36.6) was effective in reducing mean ferritin concentration and transferrin saturation from 1726.9 to 93.0 mg per L and from 54.7 to 23.3 percent, respectively. The presence of a HH gene mutation did not influence initial iron status or response to treatment. The phlebotomy program was well tolerated and no adverse events were recorded during or after collection. In three cases the time between phlebotomies was increased because of patient's poor compliance or low Hb levels. CONCLUSION: Our study shows that phlebotomies are a safe and effective method for reducing iron overload in multiply transfused long-term AL survivors with secondary hemochromatosis.
引用
收藏
页码:833 / 837
页数:5
相关论文
共 21 条
[1]   HFE genotype in patients with hemochromatosis and other liver diseases [J].
Bacon, BR ;
Olynyk, JK ;
Brunt, EM ;
Britton, RS ;
Wolff, RK .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (12) :953-962
[2]   Transfusion iron overload in adults with acute leukemia: Manifestations and therapy [J].
Barton, JC ;
Bertoli, LF .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2000, 319 (02) :73-78
[3]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[4]  
Borgna-Pignatti C, 1998, HAEMATOLOGICA, V83, P788
[5]   Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy [J].
Cassanelli, S ;
Pignatti, E ;
Montosi, G ;
Garuti, C ;
Mariano, M ;
Campioli, D ;
Carbonieri, A ;
Baldini, E ;
Pietrangelo, A .
JOURNAL OF HEPATOLOGY, 2001, 34 (04) :523-528
[6]   Hemochromatosis gene in leukemia and lymphoma [J].
Dorak, MT ;
Burnett, AK ;
Worwood, M .
LEUKEMIA & LYMPHOMA, 2002, 43 (03) :467-477
[7]   The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia [J].
Dorak, MT ;
Burnett, AK ;
Worwood, M ;
Sproul, AM ;
Gibson, BES .
BLOOD, 1999, 94 (11) :3957-3957
[8]  
Franchini M, 2000, HAEMATOLOGICA, V85, P1122
[9]   Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload [J].
Franchini, M ;
Gandini, G ;
de Gironcoli, M ;
Vassanelli, A ;
Borgna-Pignatti, C ;
Aprili, G .
BLOOD, 2000, 95 (09) :2776-2779
[10]   Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update [J].
Franchini, M ;
Gandini, G ;
Veneri, D ;
Aprili, G .
BLOOD, 2004, 103 (02) :747-748